Recent Advances: Clinical immunologyBMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7044.1465 (Published 08 June 1996) Cite this as: BMJ 1996;312:1465
- a Department of Immunology and Transfusion Medicine, Nordland Central Hospital, University of Tromso, N-8017 Bodo, Norway
- b Institute of Immunology and Rheumatology, Rikshospitalet, University of Oslo, Oslo, Norway
- Correspondence to: Dr Mollnes.
The genetic basis for many types of hereditary immunodeficiency has now been found, allowing more precise diagnosis and giving hope for future treatments
Manipulation of proteins that regulate complement activation has exciting therapeutic implications, such as ameliorating the hyperacute rejection of xenografts
Deficiencies in complement regulators have been implicated in several types of kidney disease, and soluble complement receptor 1 may be useful in future treatments
Intravenous immunoglobulin is now used to treat several systemic inflammatory conditions, and its effects include modulating proinflammatory cytokines and complement activation
Use of new technologies is allowing development of more effective vaccines and avoidance of adverse effects such as found with whole cell pertussis vaccine
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial